5-溴-1-苯基-1H-苯并咪唑 | 221636-18-6

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-溴-1-苯基-1H-苯并咪唑
• 中文别名: 5-溴-1-苯基-苯并咪唑
• 英文名称: 5-bromo-1-phenyl-1H-benzo[d]imidazole
• 英文别名: 5-bromo-1-phenyl-1H-benzoimidazole；5-bromo-1-phenylbenzimidazole
• CAS: 221636-18-6
• 化学式: C₁₃H₉BrN₂
• 分子量: 273.132
• InChiKey: OCVMHOYOAZUGSK-UHFFFAOYSA-N

物化性质

• 沸点：
  414.7±37.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-1-phenyl-1h-benzoimidazole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-1-phenyl-1h-benzoimidazole
CAS number: 221636-18-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H9BrN2
Molecular weight: 273.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-1-苯基-1H-苯并咪唑 在 四(三苯基膦)钯 、 氢溴酸 、 sodium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(1-Phenylbenzimidazol-5-yl)phenol
  参考文献：
  名称：

  Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

  摘要：

  1, 5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00485-2
• 作为产物：
  描述：

  2,5-二溴硝基苯 在 sodium sulfide 、 sodium acetate 、 sulfur 作用下， 以 水 为溶剂， 反应 13.0h， 生成 5-溴-1-苯基-1H-苯并咪唑
  参考文献：
  名称：

  带有 BODIPY 取代的 N-杂环卡宾 (NHC) 配体的中性铱 (iii) 配合物：合成、光物理学、体外治疗诊断光动力疗法和抗菌活性†

  摘要：

  报道了一系列新型中性杂配环金属化铱 ( III ) 配合物的合成、光物理和光生物学活性，这些配合物包含硼二吡咯亚甲基 (BODIPY) 取代的 N-杂环卡宾 (NHC) 配体 ( Ir1–Ir5 )。NHC配体上BODIPY的取代位置（苯环的C4（Ir1-Ir3）或苯并咪唑单元的C5（Ir4和Ir5））及其连接体类型（单键或三键）对光物理性能的影响性质进行了研究。Ir1–Ir5在 530–543 nm处表现出 BODIPY 局部强烈的1 IL（配体内跃迁）/ 1 MLCT（金属到配体电荷转移）吸收，并在582 nm 处表现出1,3 IL/ 1,3 CT（电荷转移）发射。 610 纳米。纳秒瞬态吸收结果表明，这些配合物的最低三重激发态是BODIPY局域的3 π,π*态。与配合物Ir1和Ir3中相应的吸收和发射带相比，配合物Ir4和Ir5表现出蓝移的1IL吸收和1,3IL / 1,3CT发射带

  DOI：

  10.1039/c9pp00142e

文献信息

• [EN] CINNOLINE DERIVATIVES AS AS BTK INHIBITORS<br/>[FR] DÉRIVÉS DE CINNOLINE EN TANT QU'EN TANT QU'INHIBITEURS DE LA BTK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013148603A1

  公开（公告）日：2013-10-03

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification. The compounds are inhibitors of Bruton's tyrosine kinase (BTK). This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with BTK.

  公开的是Formula 1的化合物及其药学上可接受的盐，其中R1、R2、R3、R4和R5在规范中有定义。这些化合物是Bruton酪氨酸激酶（BTK）的抑制剂。本公开还涉及制备Formula 1化合物的材料和方法，包括含有它们的药物组合物，以及它们用于治疗与BTK相关的疾病、疾病或症状的用途。
• Synthesis of Multideuterated (Hetero)aryl Bromides by Ag(I)-Catalyzed H/D Exchange
  作者：Guang-Qi Hu、Jing-Wen Bai、En-Ci Li、Kai-Hui Liu、Fei-Fei Sheng、Hong-Hai Zhang

  DOI：10.1021/acs.orglett.0c04139

  日期：2021.3.5

  deuterated architectures for various scientific applications. Traditionally, these deterium-labeled (hetero)aryl bromides are commonly prepared via multistep syntheses. Herein, we disclose a direct H/D exchange protocol for deuteration of (hetero)aryl bromides using Ag2CO3 as catalyst and D2O as deuterium source. This protocol is highly efficient, simply manipulated, and appliable for deuterium-labeling

  氘标记的（杂）芳基溴是最广泛应用的基序之一，可实现重要的氘代体系结构以用于各种科学应用。传统上，这些氘标记的（杂）芳基溴化物通常是通过多步合成法制备的。在这里，我们公开了一种直接的H / D交换协议，用于使用Ag 2 CO 3作为催化剂和D 2对（杂）芳基溴进行氘化O作为氘源。该协议高效，简单易操作，适用于55种以上（杂）芳基溴的氘标记，包括生物活性药物样分子和功能材料的关键中间体。另外，该方法显示出与现有过渡金属催化的HIE过程截然不同的位点选择性，从而一步完成了多氘代（杂）芳基溴化物。
• SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES
  申请人：Crew Andrew P.

  公开号：US20090286768A1

  公开（公告）日：2009-11-19

  Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.

  基于融合吡啶的双环化合物具有如下所定义的结构，其药学上可接受的盐，制备方法，组合物及其用于疾病治疗。本摘要不定义或限制该发明。
• Angiogenesis inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06465484B1

  公开（公告）日：2002-10-15

  The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tryrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.

  本发明涉及抑制酪氨酸激酶酶的化合物，包含抑制酪氨酸激酶的化合物的组合物以及使用酪氨酸激酶抑制剂治疗依赖酪氨酸激酶的疾病/病症，如在哺乳动物中的血管生成、癌症、动脉粥样硬化、糖尿病视网膜病变或自身免疫疾病。
• Tyrosine kinase inhibitors
  申请人：Merck & Co., Inc.

  公开号：US06162804A1

  公开（公告）日：2000-12-19

  The present invention relates to benzinidazole compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases/conditions such as angiogenenesis, cancer, atherosclerosis, diabetic retinopathy or autoimmune diseases, in mammals.

  本发明涉及抑制酪氨酸激酶酶的苯唑胺类化合物，包含抑制酪氨酸激酶的化合物的组合物，以及利用酪氨酸激酶抑制剂治疗依赖于酪氨酸激酶的疾病/症状，如血管生成、癌症、动脉粥样硬化、糖尿病视网膜病变或自身免疫疾病，在哺乳动物中的方法。